ArticleMetabolism open2025
Effect of dapagliflozin on eGFR slope in IgA nephropathy based on renal pathological assessment using image analysis software.
Article in Metabolism open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fractional Excretion of Total Protein and Long-Term Kidney Outcomes in Patients With Biopsy-Proven Diabetic Nephropathy: The N-BDN Study.Diabetes, obesity & metabolism · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Studies have examined the effect of dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, on chronic kidney disease (CKD), including immunoglobulin A nephropathy (IgAN). Dapagliflozin decreases albuminuria and slows the decline in estimated glomerular filtration rate (eGFR). However, its renoprotective effects may not be observed in all patients with IgAN in real-world clinical practice. In this study, we aimed to investigate the potential relationship between renal histopathology analyzed using imaging software and the renoprotective effects of dapagliflozin. Methods: The mesangial matrix fraction (Mes Fx) in patients with IgAN was analyzed using Image-J, an imaging software. The relationships between eGFR slope decline, changes in urinary protein, and the degree of Mes Fx before and after dapagliflozin treatment were investigated. Results: A significant correlation was evident between the degree of Mes Fx and eGFR slope decline in patients with IgAN. Furthermore, it was suggested that when the Mes Fx exceeded 10 % of the total glomerular surface area, the effect of dapagliflozin in slowing the eGFR decline was unclear. Conclusions: However, it should be noted that this study has limitations, including the absence of a control group, the small data size, and its pilot study nature. Therefore, it cannot be stated unequivocally that dapagliflozin's efficacy is definitively demonstrated by Mes Fx predictive role.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.